Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + FOLFOX4
- Development stage
- Phase 3
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Lenvatinib + FOLFOX4 is a combination therapy being investigated as an adjuvant treatment to prevent recurrence of hepatocellular carcinoma (HCC) in patients who have undergone liver transplantation and are beyond the Milan criteria. FOLFOX4 is a chemotherapy regimen consisting of oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil (5-FU). Oxaliplatin causes DNA cross-linking, 5-FU inhibits thymidylate synthase to disrupt DNA synthesis, and leucovorin enhances the binding of 5-FU to its target. Lenvatinib is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. This combination aims to provide both systemic cytotoxic effects and targeted anti-angiogenic/anti-proliferative activity to eliminate residual micrometastases post-transplant.
- Other names
- FOLFOX4 and LenvatinibFOLFOX-4 and LenvatinibFOLFOX 4 and LenvatinibFOLFOX combined with LenvatinibFOLFOX4 + lenvatinib
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + FOLFOX4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + FOLFOX4.